Replies to post #7257 on Galena Biopharma fka GALE

[Euripides90]

CAN U READ? Chief Medical Officer managing clinical development which is having very positive reaction from peers in med. community:
HE HAS NOTHING TO DO WITH PUBLIC RELATIONS.

Dr. Nejadnik will be responsible for managing all of Galena's clinical development programs, which consist of multiple mid- to late-stage clinical assets, including immunotherapy programs led by NeuVax(TM) (nelipepimut-S) and GALE-301 (Folate Binding Protein).

NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials both as a single agent and in combination with other therapies. GALE-301 recently completed a Phase 2a clinical trial in ovarian and endometrial cancer.


So with that assumption that the co.'s guilty if it PR's you can be sure the shorts will continue to have a field day with this marked --